Evozyne Funding, Investors & Competitors

Genesys is a Daly City, California-headquartered provider of AI-powered experience orchestration platforms. Genesys Cloud integrates customer data, voice, and digital channels for 8,000 global organizations including American Express and PayPal. It supports agentic AI for routing and analytics across contact centers.

Glean is a Palo Alto-headquartered enterprise search platform powered by AI connecting internal data sources. Launched in 2019, its Workplace Search tool indexes documents from Slack, Google Drive, and Salesforce to deliver context-aware answers via large language models. Adopted by Fortune 500 firms like Databricks and Duolingo, Glean processes petabytes of corporate knowledge for knowledge worker productivity.

Legora is a London-headquartered AI platform designed for legal professionals to review documents, perform research, and generate drafts. The tool automates contract analysis and case law searches while integrating with firm workflows for junior lawyers and partners. Founded in 2023, it emphasizes collaborative features that align with client-specific implementations across litigation and corporate practices.

Factory is a developer of AI agents named Droids that handle full software development tasks such as refactoring and migrations. San Francisco-headquartered, it integrates agents into IDEs, CLIs, browsers, and collaboration tools like Slack, offering enterprise-grade security for vendor-agnostic automation.

Decagon is a San Francisco-based provider of a conversational AI platform for customer support across web, mobile, and voice channels. The platform allows non-technical teams to configure AI agents using natural language prompts while developers access full code control via GitHub integration. Decagon powers support for brands like Notion and launched in 2023, enabling deployments in under four weeks without custom engineering.

Intrepid Labs is a biotechnology firm spun out of the University of Toronto in 2022. The company applies artificial intelligence and robotics to automate drug formulation processes, speeding up therapeutic development for pharmaceuticals. Its platform optimizes solid oral dosage forms by predicting formulation outcomes and reducing trial-and-error iterations. Based in Toronto, Ontario, Intrepid Labs partners with contract development organizations to enhance efficiency in early-stage drug manufacturing pipelines.

Astromech is an artificial intelligence company spun out of Colossal Biosciences, founded by Ben Lamm. It uses AI to analyze biological data and forecast evolution and disease risk, applying its platform to biotech research.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Anthropic is an AI safety company developing large language models and researching methods to make artificial intelligence more reliable and steerable. Anthropic was founded in 2021 by former OpenAI researchers including Dario and Daniela Amodei. The company's flagship product is Claude, a family of AI assistants deployed across consumer applications and enterprise APIs. Research priorities center on constitutional AI, mechanistic interpretability, and alignment techniques. Major investors include Google, Spark Capital, and Salesforce Ventures.

OpenAI is an AI research and deployment company that develops large language models, including the GPT series, and consumer-facing products such as ChatGPT. Founded in 2015 as a nonprofit research lab, the organization transitioned to a capped-profit structure in 2019 to attract the capital needed for large-scale AI development. The company offers API access to its models for enterprise and developer use, alongside image generation through DALL-E and code-assistance tools. Headquartered in San Francisco, OpenAI has become one of the most prominent players in the generative AI space, backed by a multibillion-dollar investments from Microsoft, Amazon, NVIDIA, SoftBank and many more.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Founded in Germany in 1972 by former IBM employees, SAP is the world’s largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP’s portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.